AnaptysBio Inc. (ANAB)
ANAB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 10-KT (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1370053/000119312526396696/0001193125-26-396696-index.htm. Net income: SEC 10-KT (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ANAB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001370053 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $234.6M |
| Net income | -$13.2M |
| Operating income | $226.9M |
| Net margin | -5.6% |
| Operating margin | 96.7% |
| Revenue growth | +157.0% |
| Cash | $138.2M |
| Total assets | $364.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 5.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $135.4M cash; operating cash flow $9.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 29,729,847 (2026-11-09); 27,688,470 a year earlier; 26,575,178 three years earlier. 1y figure adjusted for split (1.5-for-1 overall); 3y figure adjusted for split (1.5-for-1 overall). | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Diego, California, United States | PCAOB Form AP 2026-10-15 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $9.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $30.3M | $3.9M | -$9.5M | $135.4M | No debt tags | $191.6M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $27.5M | $183.9M | -$26.6M | $133.8M | No debt tags | $237.6M | 10-KT 2026-09-21 |
| Q1 2026 2026-03-31 | $25.6M | -$52.9M | -$25.9M | $248.5M | No debt tags | $232.4M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $108.2M | $49.6M | $98.0M | $138.2M | No debt tags | $234.6M | 10-KT 2026-09-21 |
| Q3 2025 2025-09-30 | $76.3M | $15.1M | -$27.4M | $109.8M | No debt tags | $169.5M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $22.3M | -$38.6M | -$40.2M | $44.3M | No debt tags | $123.2M | 10-Q 2025-08-06 |
| Q1 2025 2025-03-31 | $27.8M | -$39.3M | -$10.7M | $98.6M | No debt tags | $111.9M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $43.1M | -$21.8M | -$66.7M | $23.1M | No debt tags | $91.3M | 10-KT 2026-09-21 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-11-15 |
| Latest annual report | 10-KT | 2026-09-21 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-06-29 |
Source: SEC EDGAR submissions feed, 728 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.4% |
| 1 month | +1.4% |
| 3 months | -17.4% |
| Year to date | +43.1% |
| 1 year | +108.6% |
| From 52-week high | -33.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NUVB | Nuvation Bio Inc. | $3.84 | -3.76% | $1.4B |
| TYRA | Tyra Biosciences Inc. | $19.74 | -1.42% | $1.4B |
| GENB | Generate Biomedicines Inc. | $10.49 | -13.09% | $1.4B |
| URGN | UroGen Pharma Ltd. | $28.10 | +7.33% | $1.4B |
| GPCR | Structure Therapeutics Inc. | $18.57 | -7.15% | $1.3B |
| LBRX | LB Pharmaceuticals Inc | $42.99 | -0.05% | $1.4B |
| DMRA | Damora Therapeutics Inc. | $22.50 | +4.14% | $1.4B |
| AVLN | Avalyn Pharma Inc. | $29.76 | -1.72% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier